Furthermore, increased expression of the SRCs could have a dual effect, one to enhance ERβ action as a suppressor of mammary cancer and the other to stimulate “normal” levels of ER-α to enhance tumor-promoting effects. The gene discussed is ESR2; the disease is neoplasm.